CML patients treated with imatinib can achieve complete morphologic remission, durable for many years, but retain HSC clones that harbor the BCR-ABL translocation that is the hallmark of the disease (75). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.